The pace at which targetable tumor-specific molecular alterations have been identified over the past decade have ushered in an era of precision oncology, yielding significant insights into the diversity of cancer, offering diagnostic and prognostic benefits, and guiding therapy selection. Indeed, guidelines emphasize that comprehensive biomarker testing should be conducted to identify actionable mutations in non-small-cell lung cancer (NSCLC), including ALK, EGFR, KRAS, MET, RET, and ERBB2 (HER2). These tests guide the selection of targeted therapies that can inhibit oncogenic pathways directly implicated in tumor growth and progression. However, comprehensive molecular testing continues to be underused, especially in community hospital settings. Underlying reasons are many and varied, and include lack of clinical knowledge, lack of multidisciplinary support in the interpretation of test results, shortcomings in tissue samples, lack of access to tests, reimbursement challenges, and turnaround times. Quality improvement (QI) programs are well suited to facilitate adoption of system-level solutions to improve guideline recommended testing of patients with NSCLC, including in patients with HER2 (ERBB2) mutations; To improve guideline recommended testing of patients with NSCLC, including in patients with HER2 (ERBB2) mutations, implementation-focused educational programs facilitating system- and process-related changes along with formalized training cascades are key to mitigating barriers. This interactive practice guide offers interventions for both team training and infrastructure building in a cost effective and high impact way. Learners can identify solutions most relevant to their scope of practice and areas of need. Don t delay! Start improving your NSCLC biomarker testing to optimize treatment processes and practices now!
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
83% of listed courses are free
45 of 54 courses listed here are free.
Collected from the provider’s public pages · source
Top 6 courses
-
-
-
ECHO-Chicago: Pediatric ADHD & Autism
15 Credits
-
-
-
Specialties served/covered
- Addiction Medicine
- Allergy & Clinical Immunology
- Cardiovascular Disease
- Child & Adolescent Psychiatry
- Clinical Cardiac Electrophysiology
- Communication & Shared Decision-Making
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Hematology
- Hospice & Palliative Medicine
- Infectious Disease
- Maternal-Fetal Medicine
- Medical Genetics & Genomics
- Medical Oncology
- Neonatal-Perinatal Medicine
- Nephrology
- Neurology
- Neuroradiology
- Neurosurgery
- Pain Medicine
- Patient Safety & Quality Improvement
- Pediatric Hematology-Oncology
- Practice Management & Ethics
- Rheumatology
- Cardio-Vascular
- Cross-Specialty
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Online course / module
- includes Board review / self-assessment
- Credit · Up to 2.5 credits
- Commercial Support
-
ReleasedApr 1, 2026
-
Last day to claim creditApr 2, 2027 6 months left
-
University of Chicago School of Medicine Out-of-the-Box Solutions for Building Clinical Capacity in Community Settings to Improve Standardized ERBB2 (HER2) Testing in NSCLC
-
University of Chicago School of Medicine Navigating Complexity in the Post-CDK4/6 Inhibitor Treatment Setting for Patients With ER+/HER2- mBC: Strategies for Optimally Integrating Next-Generation Oral SERDs
-
University of Chicago School of Medicine Sustainable and Scalable Strategies for Safe and Effective Administration of Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma in Outpatient and Community Settings
